The effect of Metformin on complication of strokes

The evaluation of the effect of Metformin on complication of ischemic strokes

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160318027097N5

Enrollment

100

Registered

2017-12-03

Start date

2017-12-06

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke. Stroke, not specified as haemorrhage or infarction

Interventions

Intervention 1: Intervention group: Tablet Metformin 500mg oral, twice in a day for 7 days. Intervention 2: Control group: Placebo oral, twice in a day for 7 days.

Treatment - Drugs

Intervention group: Tablet Metformin 500mg oral, twice in a day for 7 days

Control group: Placebo oral, twice in a day for 7 days

Eligibility

Sex/Gender

All

Age

20 Years to 100 Years

Inclusion criteria

Inclusion criteria: Ischemic stroke patients; focal neurological symptoms.

Exclusion criteria

Exclusion criteria: intracerebral hemorrhage (ICH); subarachnoid hemorrhage (SAH); subdural hematoma (SDH); hypoglycemia; contraindications for metformin use; diabetic patients; venous sinus thrombosis; drug side effects.

Design outcomes

Primary

Measure	Time frame
The stroke clinical manifestations. Timepoint: Befor the intervention, 24 hours, 48 hours, 168 hours, 1 month, 2 months, 3 months after the intervention. Method of measurement: National Institutes Of Health Stroke Scale.	—

Secondary

Measure	Time frame
-. Timepoint: -. Method of measurement: -.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Vahid Abbasi

Ardebil University of Medical Sciences

V.Abasi@arums.ac.ir+98 45 3351 2006

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026